Anti-viral paints and coatings and articles comprising same
Disclosed herein are material composition formulated for mitigating activity of a virus on a surface of an article. Methods of preparing such a material composition are also disclosed.
1. A method for mitigating contamination of a surface by particles of at least a coronavirus for which an enveloped bacterial virus having a lipid-rich viral membrane envelope is a biological surrogate, comprising:
applying an anti-viral functionalized coating composition on a surface of a substrate to create an anti-viral functionalized surface thereof, wherein the anti-viral functionalized coating composition comprises an effective amount of an anti-viral additive admixed with a specified amount of a polymeric coating composition, wherein the anti-viral additive comprises antimicrobial peptide and lipolytic enzyme, wherein said antimicrobial peptide comprises SEQ ID NO. 40, wherein the effective amount of said antimicrobial peptide and the specified amount of said lipolytic enzyme jointly cause the anti-viral functionalized surface to provide an additive-induced amount of infective particles of the biological surrogate when the biological surrogate is brought into contact with the anti-viral functionalized surface that is at least 70% less than a baseline amount of infective particles of the biological surrogate, wherein a surface of a layer of the polymeric coating composition on the surface of the substrate supports presence of the baseline amount of infective particles of the biological surrogate when the biological surrogate is brought into contact with the surface of the layer of the polymeric coating composition.
2. The method of claim 1 wherein the infective particles of the biological surrogate are infective PHI-6 bacteriophage particles.
3. The method of claim 1 wherein said lipolytic enzyme comprises lipase.
4. The method of claim 3 wherein the anti-viral functionalized coating composition provides an additive-induced amount of infective particles of the biological surrogate brought into contact with the anti-viral functionalized surface that is at least 80% less than the baseline amount of infective particles of the biological surrogate.
5. The method of claim 4 wherein the infective particles of the biological surrogate are infective PHI-6 bacteriophage particles.
6. The method of claim 3 wherein:
said antimicrobial peptide is present within the polymeric coating composition at a concentration of about 3% total solids; and
said lipolytic enzyme is present within the polymeric coating composition at a concentration of about 1.5% total solids.
7. The method of claim 6 wherein:
said antimicrobial peptide consists of SEQ ID NO. 40; and
said lipolytic enzyme consists of lipase.
8. The method of claim 1 wherein:
the infective particles of the biological surrogate are infective PHI-6 bacteriophage particles; and
said lipolytic enzyme comprises lipase.
9. The method of claim 8 wherein the polymeric coating composition comprises water-based polyurethane.
10. The method of claim 8 wherein:
said antimicrobial peptide is present within the polymeric coating composition at a concentration of about 3% total solids; and
said lipolytic enzyme is present within the polymeric coating composition at a concentration of about 1.5% total solids.
11. The method of claim 10 wherein the anti-viral functionalized coating composition provides an additive-induced amount of infective particles of the biological surrogate brought into contact with the anti-viral functionalized surface that is at least 80% less than the baseline amount of infective particles of the biological surrogate.
12. The method of claim 1 wherein the polymeric coating composition comprises water-based polyurethane.
13. The method of claim 12 wherein said lipolytic enzyme comprises lipase.
14. The method of claim 13 wherein the infective particles of the biological surrogate are infective PHI-6 bacteriophage particles.
15. The method of claim 12 wherein the anti-viral functionalized coating composition provides an additive-induced amount of infective particles of the biological surrogate brought into contact with the anti-viral functionalized surface that is at least 80% less than the baseline amount of infective particles of the biological surrogate.
16. The method of claim 12 wherein:
said antimicrobial peptide is present within the polymeric coating composition at a concentration of about 3% total solids; and
said lipolytic enzyme is present within the polymeric coating composition at a concentration of about 1.5% total solids.
17. The method of claim 16 wherein said lipolytic enzyme comprises lipase.
18. The method of claim 16 wherein:
said antimicrobial peptide consists of SEQ ID NO. 40; and
said lipolytic enzyme consists of lipase.
19. The method of claim 1 wherein the polymeric coating composition comprises an oil-modified polyurethane dispersion resin.
20. The method of claim 19 wherein said lipolytic enzyme comprises lipase.
21. The method of claim 20 wherein the infective particles of the biological surrogate are infective PHI-6 bacteriophage particles.
22. The method of claim 19 wherein the anti-viral functionalized coating composition provides an additive-induced amount of infective particles of the biological surrogate brought into contact with the anti-viral functionalized surface that is at least 80% less than the baseline amount of infective particles of the biological surrogate.
23. A method for mitigating contamination of a surface by particles of at least a coronavirus for which an enveloped bacterial virus having a lipid-rich viral membrane envelope is a biological surrogate, comprising:
forming a layer of an anti-viral functionalized coating composition on a surface of a substrate to create an anti-viral functionalized surface, wherein the anti-viral functionalized coating composition comprises an effective amount of an anti-viral additive admixed with a specified amount of a polymeric coating composition, wherein the anti-viral additive comprises antimicrobial peptide and lipolytic enzyme, wherein said antimicrobial peptide comprises SEQ ID NO. 40, wherein the effective amount of said antimicrobial peptide and the specified amount of said lipolytic enzyme jointly cause the anti-viral functionalized surface to provide an additive-induced amount of infective particles of the biological surrogate when the biological surrogate is brought into contact with the anti-viral functionalized surface that is at least 70% less than a baseline amount of infective particles of the biological surrogate, wherein a surface of a layer of the polymeric coating composition on the substrate supports presence of the baseline amount of infective particles of the biological surrogate when the biological surrogate is brought into contact with the surface of the layer of the polymeric coating composition.
24. The method of claim 23 wherein said lipolytic enzyme comprises lipase.
25. The method of claim 23 wherein:
said antimicrobial peptide consists of SEQ ID NO. 40; and
said lipolytic enzyme consists of lipase.